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BACKgrounD: Enterococci are an important cause of central 
venous catheter (CVC)-associated bloodstream infections (CA-BSI). 
It is unclear whether CVC removal is necessary to successfully manage 
enterococcal CA-BSI. 
MEthoDs: A 12-month retrospective cohort study of adults with 
enterococcal CA-BSI was conducted at a tertiary care hospital; clini-
cal, microbiological and outcome data were collected. 
rEsuLts: A total of 111 patients had an enterococcal CA-BSI. The 
median age was 58.2 years (range 21 to 94 years). There were 45 (40.5%) 
infections caused by Entercoccus faecalis (among which 10 [22%] were 
vancomycin resistant), 61 (55%) by Enterococcus faecium (57 [93%] 
vancomycin resistant) and five (4.5%) by other Enterococcus species. 
Patients were treated with linezolid (n=51 [46%]), vancomycin 
(n=37 [33%]), daptomycin (n=11 [10%]), ampicillin (n=2 [2%]) or 
quinupristin/dalfopristin (n=2 [2%]); seven (n=6%) patients did not 
receive adequate enterococcal treatment. Additionally, 24 (22%) 
patients received adjunctive gentamicin treatment. The CVC was 
retained in 29 (26.1%) patients. Patients with removed CVCs showed 
lower rates of in-hospital mortality (15 [18.3%] versus 11 [37.9]; 
P=0.03), but similar rates of recurrent bacteremia (nine [11.0%] versus 
two (7.0%); P=0.7) and a similar post-BSI length of hospital stay 
(median days [range]) (11.1 [1.7 to 63.1 days] versus 9.3 [1.9 to 
31.8 days]; P=0.3). Catheter retention was an independent predictor 
of mortality (OR 3.34 [95% CI 1.21 to 9.26]).
ConCLusIons: To the authors’ knowledge, the present article 
describes the largest enterococcal CA-BSI series to date. Mortality was 
increased among patients who had their catheter retained. Additional 
prospective studies are necessary to determine the optimal manage-
ment of enterococcal CA-BSI.
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Management
Le retrait ou le maintien du cathéter dans la prise 
en charge des bactériémies liées à un cathéter
hIstorIQuE : Les entérocoques constituent une cause importante 
de bactériémies liées à un cathéter veineux central (CVC). On ne sait 
pas s’il est nécessaire de retirer le CVC pour réussir la prise en charge 
de ce type de bactériémie.
MÉthoDoLogIE : Les auteurs ont mené une étude rétrospective de 
cohorte de 12 mois auprès d’adultes ayant une bactériémie liée à un 
CVC dans un hôpital de soins tertiaires. Ils ont colligé des données 
cliniques, des données microbiologiques et des données d’issue.
rÉsuLtAts : Au total, 111 patients étaient atteints d’une bactériémie 
à entérocoque liée à un CVC. Ils avaient un âge médian de 58,2 ans 
(plage de 21 à 94 ans). Les chercheurs ont constaté 45 infections 
(40,5 %) causées par l’Enterococcus faecalis (dont 10 [22 %] résistantes 
à la vancomycine), 61 infections (55 %) causées par l’Enterococcus 
faecium (dont 57 [93 %] résistantes à la vancomycine) et cinq (4,5 %) 
causées par d’autres espèces d’Enterococcus. Les patients ont été trai-
tés au linézolide (n=51 [46 %]), à la vancomycine (n=37 [33 %]), à 
la daptomycine (n=11 [10 %]), à l’ampicilline (n=2 [2 %]) ou à la 
quinupristine-dalfopristine (n=2 [2 %]). Sept patients (n=6 %) n’ont 
pas reçu de traitement convenable contre les entérocoques. De plus, 
24 patients (22%) ont reçu un traitement d’appoint à la gentamicine. 
Vingt-neuf patients (26,1 %) ont conservé leur CVC. Les patients à 
qui on l’avait retiré présentaient des taux de mortalité hospitalière 
plus faibles (15 [18,3 %] par rapport à 11 [37,9]; P=0,03), mais des 
taux similaires de bactériémie récurrente (neuf [11,0 %] par rapport à 
deux (7,0 %); P=0,7) et une durée d’hospitalisation similaire après la 
bactériémie (jours médians [plage]) (11,1 [1,7 à 63,1 jours] par rapport 
à 9,3 [1,9 à 31,8 jours]; P=0,3). Le maintien du cathéter était un pré-
dicteur indépendant de mortalité (RRR 3,34 [95 % IC 1,21 à 9,26]).
ConCLusIons : En autant que le sache les auteurs, le présent arti-
cle décrit la plus grosse série de bactériémies liées à un CVC. La mor-
talité était plus élevée chez les patients qui conservaient leur cathéter. 
D’autres études prospectives s’imposent pour déterminer la prise en 
charge optimale de la bactériémie à entérocoque liée à un CVC.
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Enterococci are the third most frequent cause of nosocomial bloodstream infections, constituting 9.4% to 11.1% of the patho-
gens recovered in two large United States studies (1,2). They also 
rank as the third most frequent bacterial cause of catheter-associated 
bloodstream infections (CA-BSI) (3). Clinical isolates most com-
monly belong to one of two subspecies, Enterococcus faecalis and 
Enterococcus faecium (4). Biofilm formation has been observed 
more frequently both in device-related bloodstream infections due 
to E faecalis (5) and E faecium (6) when compared with other sources 
of infection or commensal enterococci, respectively. It has, there-
fore, been suggested as a marker of virulence. Biofilm formation also 
decreases local antimicrobial susceptibility (7,8). Because eradica-
tion of an established biofilm from an indwelling device is difficult to 
achieve, some experts recommend removing catheters in the setting 
of enterococcal bloodstream infection (9). However, enterococcal 
CA-BSI as a separate entity have been infrequently investigated 
(10-12) and the recommendation to remove the catheter is based on 
the findings of a single retrospective study (11). On the other hand, 
there are disadvantages to catheter replacement including material 
and procedural costs, and potential adverse events related to the 
insertion procedure.
The aim of the present study was to examine the epidemiology, 
treatment and subsequent outcomes of patients with enterococcal 
CA-BSI, comparing patients with retained versus removed catheters. 
Our hypothesis was that catheter management does not affect patient 
outcomes.
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MEthoDs
setting
Barnes-Jewish Hospital (BJH), a 1250-bed teaching hospital, is the 
largest hospital in Missouri (USA), and has a referral base that 
includes the St Louis Metropolitan area, eastern Missouri and western 
Illinois. It houses all medical specialties, including a stem cell trans-
plantation unit. BJH is affiliated with the Washington University 
School of Medicine (St Louis, Missiouri, USA).
study design
A retrospective cohort study of patients with enterococcal CA-BSIs 
during their hospital stay was performed. CA-BSI was defined as 
enterococcal bacteremia in a patient with a central venous catheter 
(CVC) in place for at least 48 h and no alternative source of infection. 
The hospital’s medical informatics database was queried for blood 
cultures positive for any Enterococcus species; this dataset was merged 
with a manually collected dataset of CVC usage in the hospital, which 
is part of the hospital infection control database.
Inclusion and exclusion criteria
Adult patients admitted to BJH between January 1, 2006 and 
December 31, 2006, who presented with, or developed, an enterococ-
cal bloodstream infection and had a CVC present at the time of detec-
tion of this infection were included. All types and locations of CVCs 
were included. Blood cultures were obtained during routine care either 
peripherally and/or from the CVC. Patients who presented to the 
hospital with a CVC already in place were included. Patient history 
and physical examination as well as admitting diagnosis and micro-
biology results were reviewed to determine whether the catheter was 
the primary focus of the bacteremia. Patients with a primary focus of 
bacteremia other than the catheter, patients with a CVC in place for 
<48 h, and patients who died on the day of the positive blood culture 
were excluded. Polymicrobial infections were included except concur-
rent Staphylococcus aureus bacteremia or candidemia within ±3 days of 
the enterococcal bacteremia (n=20) because both entities are estab-
lished indications for catheter removal.
Data collection
Demographic characteristics, medical history, clinical presentation, 
diagnostic and therapeutic procedures, antibiotic treatment and key 
markers of outcome (recurrence of bloodstream infection, length of 
hospital stay after the bloodstream infection, crude mortality) were 
abstracted from the medical records. Admission Charlson comorbidity 
and McCabe severity of illness scores were determined. Duration of 
catheter retention time after the bacteremia was recorded. Information 
on antibiotic lock therapy was collected; however, this treatment 
modality was not used in patients from this cohort.
Postdischarge mortality at both 30 days and three months after 
bacteremia was obtained from the Social Security Death Index (www.
ssdi-search.com).
Definitions
Renal insufficiency was defined by a serum creatinine level >132.6 μmol/L. 
Sepsis and sepsis-induced hypotension were defined using established 
criteria (13). Appropriate therapy was defined as pathogen-directed 
treatment with antibiotics matching susceptibilities. A catheter was 
considered to be retained if it was present for the duration of the hos-
pitalization after the first positive blood culture. Recurrence of bacter-
emia (used here synonymously with intermittent bacteremia) was 
defined as a second positive blood culture after ≥1 negative blood 
culture and an interval of ≥1 day during their hospitalization. 
Community-onset enterococcal bloodstream infection was defined as 
having the first positive blood culture drawn within 48 h of hospital 
admission. 
Data analysis and statistical methods
Data entry was performed using Access and Excel (Microsoft 
Corporation, USA). Data analysis was performed using SPSS 17 (IBM 
Corporation, USA). Univariate comparisons among categorical vari-
ables and outcome measures were performed using the χ2 test or 
Fisher’s exact test. A two-sided P <0.05 was considered to be statistic-
ally significant. Also calculated was the absolute difference in propor-
tion (∆p) of rates of outcome measures including the 95% CI of this 
difference to describe the precision of this point estimate. Analysis of 
the difference in proportions and 95% CI enabled the interpretation of 
statistical significance (if the 95% CI did not cross zero) as well as 
clinical significance (if the upper limit of the 95% CI exceeded a pre-
defined difference). An absolute difference in recurrence of bacter-
emia and mortality rates of 15% was considered to represent a 
clinically significant difference; this estimate was chosen based on 
previous literature regarding catheter management and clinical experi-
ence (14,15). Comparisons among continuous independent variables 
were performed using the Student’s t test or Mann-Whitney U test as 
appropriate. Variables found to have P<0.1 in univariate testing were 
considered for entry into a forward, stepwise multivariate logistic 
regression model. 
The study was approved by the Washington University Human 
Research Protection Office (#07-0690).
rEsuLts
Demographics, comorbidities and clinical presentation
There were 111 patients with enterococcal CA-BSI who met inclu-
sion criteria. The mean (± SD) age was 58.2±15.3 years; 56 (50.5%) 
patients were male; and 77 (69.4%) were white. There were 36 (32%) 
patients admitted to the oncology/bone marrow transplant service. 
The most frequent comorbidities were malignancies (n=62 [55.9%]), 
diabetes (n=35 [31.5%]) and renal insufficiency (n=31 [27.9%]). 
Twenty-five (22.5%) patients had metastatic solid tumours, 28 (25.2%)
had leukemia, six (5.4%) had lymphomas and three (2.7%) had non-
metastatic solid tumours. There were 20 (18%) patients who were 
neutropenic at the time of bloodstream infection. Of all bloodstream 
infections, 90 (81%) were hospital-acquired. None of the patients 
were diagnosed with infective endocarditis during the admission.
Microbiology
Of the enterococcal bloodstream infections, 45 (40.5%) were caused 
by E faecalis and 61 (55.0%) by E faecium. Of the bacteremias caused 
by E faecalis, 10 (22.2%) were due to vancomycin-resistant isolates 
while 57 (93.4%) of the bacteremias caused by E faecium were vanco-
mycin resistant. An additional five (4.5%) infections were caused by 
other Enterococcus species. A total of 37 patients (33.3%) had poly-
microbial infections in which the most common polymicrobial 
organism was coagulase-negative Staphylococcus (n=26 [23.4%]). There 
were 24 (34.9%) polymicrobial E faecalis bacteremias and 10 (27.0%) 
polymicrobial E faecium bacteremias. Additionally, there was no dif-
ference in polymicrobial bacteremias among patients who had their 
catheter removed versus retained (28 [34.1%] versus nine [31.0%]; 
P=0.8).
Vancomycin-susceptible E faecalis caused 30 (36.6%) of 82 infec-
tions in which catheters were removed during the hospitalization and 
five (17.2%) of 29 infections in which they were retained (P=0.09). 
Vancomycin-resistant E faecium (VRE) caused 42 (51.2%) of infec-
tions in which catheters were removed and 15 (51.7%) in which they 
were retained (P=0.9). Overall, there was no difference in the num-
ber of vancomycin-resistant isolates regardless of whether a catheter 
was removed (49 of 82 [59.8%] versus 18 of 29 [62.1%]; P=1.0). Of 
the 26 patients who died during hospitalization, 19 (73.1%) had 
vancomycin-resistant enterococcal bacteremia.  
Antibiotic treatment
Patients were treated most frequently with linezolid (n=51 [45.9%]) or 
vancomycin (n=37 [33.3%]). Smaller subsets were given daptomycin 
(n=11 [9.9%]), ampicillin (n=2 [1.8%]) or quinupristin/dalfopristin 
(n=2 [1.8%]). Of the seven (6.3%) patients who did not receive 
adequate enterococcal treatment, five had their catheter removed 
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during the admission. In addition to one of the antibiotics above, 
24 (21.6%) patients received adjunctive treatment with gentamicin. 
Due to discharge or in-hospital mortality, the mean duration of in-
hospital antibiotic treatment was limited to 10.0±8.0 days. Data 
regarding postdischarge antibiotics were not collected.
Catheter management
The CVC was retained during the hospitalization in 29 (26.1%) 
patients. In univariate analysis, patients with removed CVCs were 
similar to patients whose CVC was retained (Table 1).
In terms of outcomes, however (Table 2), patients with removed 
CVCs showed both lower in-hospital mortality (15 [18.3%] versus 
11 [37.9%]; ∆p=16% [95% CI 2% to 39%]; P=0.03), and lower 30-day 
mortality (21 [25.6%] versus 13 [44.8%]; ∆p=16% [95% CI −0.2% to 
39%]; P=0.05). In contrast, rates were similar in patients who had 
their CVC removed or retained for recurrent bacteremia (nine [11.0%] 
versus two [7.0%]; ∆p=4% [95% CI −14% to 12%]; P=0.7), median 
(range in days) post-bacteremia length of hospital stay (11.1 [1.7 to 
63.1 days] versus 9.3 [1.9 to 31.8 days]; ∆p =1.8 days [95% CI −2.1 to 
5.6 days]; P=0.31) and three-month mortality (32 [39.0%] versus 
15 [51.7%]; ∆p=10% [95% CI −8% to 32%]; P=0.2). 
risk factors for mortality
A number of risk factors for mortality were identified in univariate 
analyses (Table 3). Patients who had VRE detected in stool were more 
likely to die in the hospital (19 of 58 [32.8%] versus five of 42 [11.9%] 
with negative VRE screening; P=0.02), as were those with E faecium 
bloodstream infection (18 of 61 [29.5%] versus eight of 50 [16.0%] 
with other enterococcal species; P=0.09), and patients managed with 
CVC retention (11 of 29 [37.9%] versus 15 of 82 [18.3%] in whom the 
CVC was removed; P=0.03). 
These three factors – VRE colonization, E faecium bloodstream 
infection and catheter retention – were entered in a multivariate 
model using logistic regression. The analysis showed that VRE col-
onization (OR 3.19 [95% CI 1.02 to 10.01]) and catheter retention 
(OR 3.34 [95% CI 1.21 to 9.26]) were independently associated with 
in-hospital mortality. 
DIsCussIon
Removal of an intravascular catheter is, with few exceptions, con-
sidered to be an essential part of managing CA-BSI. However, robust 
data to support this approach are only available for a limited number 
of pathogens responsible for these infections. Despite the lack of suf-
ficient data to provide an evidence-based recommendation with 
regard to CA-BSI caused by Enterococcus species, national guidelines 
recommend removing the involved catheters (9). To our knowledge, 
the present study represents the largest investigation into catheter 
management and outcomes of enterococcal bloodstream infections. 
The main finding of the present study was increased mortality in 
patients whose catheters were retained during the hospitalization. Our 
findings suggest that catheter removal should be considered to improve 
patient survival. Also, the difference in the two outcome proportions 
exceeded the predetermined clinically meaningful difference of 15%, 
which gives us a quantitative estimate of the impact of catheter 
removal. The patient groups were very similar with respect to demo-
graphic characteristics and comorbidities, including adjunctive anti-
biotic treatment with the aminoglycoside gentamicin. These findings 
are congruent with the single study encountered in the scientific lit-
erature that scrutinized outcomes of enterococcal CA-BSI and specif-
ically investigated catheter management, albeit in a smaller number of 
Table 2
Comparison of outcome measures of patients with 
enterococcal catheter-associated bloodstream infections 














9 (11.0) 2 (7.0) 0.72 4 (−14% to 12%)
In-hospital crude 
mortality
15 (18.3) 11 (37.9) 0.03 16 (2% to 39%)
Mortality within 
30 days of the 
first positive 
culture
21 (25.6) 13 (44.8) 0.05 16 (−0.2% to 39%)
Mortality within 
three months of 
the first positive 
culture
32 (39.0) 15 (51.7) 0.23 10 (−8% to 32%)
*Δp represents the difference in proportions between the two catheter man-
agement groups; †The 95% CI represents the precision of this estimate by 
describing statistical significance (95% CI does not cross 0) as well as clinical 
significance (the upper bound of the 95% CI exceeds the predetermined ‘clini-
cally significant’ change in outcome rates of 15%)
Table 1
Comparison of characteristics of patients with 
enterococcal catheter-associated bloodstream infections 









Demographics and clinical characteristics
Age, years, mean ± SD 58.7±15.6 56.6 ±14.7 0.52
Charlson comorbidity index score,  
   mean ± SD
3.1±3.0 3.4 ±3.4 0.58
McCabe severity score, mean ± SD 2.0±0.82 1.8±0.76 0.29
Service on admission
General internal medicine 29 (35.4) 10 (34.5) 0.93
Oncology/bone marrow transplant 25 (30.5) 11 (37.9) 0.46
Comorbidities
Malignant tumour 46 (56.1) 16 (55.2) 0.93
Diabetes mellitus 27 (32.9) 8 (27.6) 0.59
Renal insufficiency (Cr >132.6 μmol/L) 22 (26.8) 9 (31.0) 0.66
Metastatic solid tumour 18 (22.0) 7 (24.1) 0.81
Sepsis 71 (86.6) 25 (86.2) 1.00
Sepsis-induced hypotension 28 (34.1) 12 (41.4) 0.49
Multiorgan dysfunction 7 (8.5) 1 (3.4) 0.68
Neutropenic at time of positive  
   blood culture
17 (20.7) 3 (10.3) 0.27
Microbiology
Enterococcus faecalis 37 (45.1) 8 (27.6) 0.10
E faecalis, vancomycin resistant 7 (8.5) 3 (10.3) 0.72
Enterococcus faecium 44 (53.7) 17 (58.6) 0.64
E faecium, vancomycin resistant 42 (51.2) 15 (51.7) 0.87
Polymicrobial bacteremia 28 (34.1) 9 (31.0) 0.76
VRE detection in stool  
   (tested in n=100)
41/82 (50.0) 17/29 (58.6) 0.42
Treatment
Duration of antibiotic treatment,  
   days, mean ± SD
10.8±8.4 7.5±6.0 0.06
Adjunctive gentamicin treatment 19 (23.2) 5 (17.2) 0.50
Data presented as n (%) unless otherwise indicated. Cr Creatinine; VRE 
Vancomycin-resistant Enterococcus faecium
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patients (11). There, the authors retrospectively examined 61 entero-
coccal CA-BSI, with 82% of the episodes due to E faecalis and polym-
icrobial infections found in 18% of the study population. Of note, they 
did not exclude patients with concurrent Staphylococcus aureus or yeast 
bloodstream infections, although these infections likely guided cath-
eter management significantly more than the detection of enterococci. 
Sandoe et al (11) evaluated whether successful treatment of a blood-
stream infection was possible without removal of the catheter, which 
was achieved in five of 13 cases (38%). If the catheter was removed, 
the chance for cure was higher (40 of 48 [83%]). They found a com-
bination of a cell wall-active agent with an aminoglycoside to be sig-
nificantly more effective than monotherapy when the catheter was 
retained. The authors concluded that, although the removal of the 
catheter was performed in the majority of cases, it did not appear to be 
a necessary part of the management as long as antimicrobial treatment 
was optimized. In our study, even though we did not set cure as an end 
point, 67 (81.7%) of 82 patients with catheters removed survived the 
hospital admission and 61 (74.4%) survived at 30 days postbacteremia. 
These rates were much lower for patients with retained catheters. In 
summary, these data suggest that although enterococcal CA-BSI are 
not an absolute indication for catheter removal, removal should be 
favoured over catheter retention.
Reasons for catheter retention may have been that the treating 
physicians of patients who were severely ill at the time of enterococcal 
bloodstream infection were reluctant to remove the catheter because 
it was essential for nonantibiotic medications; that the patients had 
limited options for alternative intravenous access; or that their comor-
bidities increased the risk of catheter removal and replacement. 
Catheter management may have been driven by reasons other than 
the infection alone, and removing the catheter could have been a 
lower priority or higher risk in the patients’ overall medical manage-
ment. Because we collected crude mortality data, it is also conceivable 
that patients died from causes not related to the CA-BSI. Of note, we 
did not observe a difference in recurrence of infection depending on 
catheter management; it is possible that the size of the cohort pre-
vented us from noting a statistically significant difference.
Our patients are notable for a high percentage of comorbid condi-
tions, including metastatic solid tumours (23%) and leukemia (25%); 
accordingly, the crude in-hospital mortality rate was high in our study 
population. An independent factor associated with death was the 
detection of VRE in the stool, which may be a marker for frequent 
health care exposure. Despite this finding, CA-BSIs with vancomycin-
resistant E faecium did not result in increased mortality compared with 
non-VRE infections. This is different from an earlier prospective study 
and a more recent meta-analysis, in which vancomycin resistance was 
found to be associated with increased mortality (16,17). Most likely, 
we could not replicate this association due to the small sample size. 
However, the association of VRE colonization with mortality has been 
demonstrated previously in a cohort of bone marrow transplant 
patients (18).
Limitations of the present study include its retrospective design, 
the fact that the diagnosis of recurrent infection depended on the 
treating physician ordering blood cultures and that postdischarge out-
comes, including completion of planned antibiotic therapy, follow-up 
blood cultures, and catheter removal postdischarge, were not studied. 
In addition, catheter management is potentially influenced by other 
reasons for retention (difficulty of finding alternative access, bleeding 
diathesis) and we did not report outcomes for different catheter types. 
Finally, changes in the usage of daptomycin and linezolid have 
occurred since the time of the study. Although this was the largest 
study of enterococcal CA-BSI to date, it is still a relatively small sam-
ple to detect rare outcomes. 
ConCLusIons
Based on our study findings, catheter removal is preferable to retention 
in patients with enterococcal CA-BSI. A large prospective or multi-
centre study should be performed to identify patients at highest risk for 
mortality and to add strength to our results. 
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Risk factors for hospital mortality in patients with 









Age, years, mean ± SD 59.0±17.3 57.9±14.8 0.8
Male sex 13 (50.0) 43 (50.6) 1.0
Body mass index, kg/m2 29.9 (9.0) 28.4 (7.2) 0.4
Comorbidities
Charlson comorbidity index  
   score, mean ± SD
4.3±4.5 2.8±2.4 0.1
Malignant tumour 15 (57.7) 44 (51.8) 0.6
Diabetes mellitus 11 (42.3) 24 (28.2) 0.2
Renal insufficiency  
   (Cr >132.6 μmol/L)
9 (34.6) 22 (25.9) 0.4
Metastatic solid tumour 5 (19.2) 20 (23.5) 0.6
Sepsis 24 (92.3) 72 (84.7) 0.5
Sepsis-induced hypotension 14 (53.8) 26 (30.6) 0.03
Multiorgan dysfunction 6 (23.1) 2 (2.4) 0.002
Development of neutropenia 7 (26.9) 19 (22.4) 0.6
Neutropenic at time of positive  
   blood culture
3 (11.5) 17 (20.0) 0.4
Hospital-acquired CA-BSI 23 (88.5) 67 (78.8) 0.4
Recurrence of enterococcal  
   bloodstream infection
5 (19.2) 6 (7.1) 0.1
Microbiology
Enterococcus faecalis 8 37 0.2
E faecalis, vancomycin-resistant 2 8 1.0
Enterococcus faecium 18 43 0.09 1.37  
(0.48-3.90)
E faecium, vancomycin-resistant 17 40 0.1
Polymicrobial bacteremia 7 (26.9) 30 (35.7) 0.4
VRE detection in stool, n/n (%)  





0.02 3.19  
(1.12-10.01)
Treatment
Catheter retained 11 (42.3) 18 (21.2) 0.03 3.34  
(1.21-9.26)
Duration of antibiotic treatment,  
    days, mean ± SD
9.2±7.4 10.2±8.2 0.6
Adjunctive gentamicin treatment 8 (30.8) 16 (18.8) 0.2
Data presented n (%) unless otherwise indicated. Cr Creatinine; VRE 
Vancomycin-resistant E faecium
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